Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-07

Study Completion Date

2018-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation trial of Sanaria's irradiated sporozoite vaccine (PfSPZ vaccine). The primary objective of this protocol is to determine the safety and reactogenicity of the PfSPZ Vaccine in malaria-experienced healthy adults. The study duration shall be 34 months and subject participation duration shall be 15-26 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

NCT01988636

Malaria

COMPLETED PHASE1

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali

NCT02627456

Malaria

COMPLETED PHASE1

Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

NCT06652737

Malaria Falciparum Malaria Infection

RECRUITING PHASE1

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

NCT03510481

Malaria

COMPLETED PHASE1

PfSPZ Vaccine Trial in Malian Children

NCT04940130

Malaria Malaria,Falciparum

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation trial of Sanaria's irradiated sporozoite vaccine (PfSPZ vaccine). The primary objective of this study is to determine the safety and reactogenicity of the PfSPZ Vaccine in malaria-experienced healthy adults. The secondary objective is to evaluate vaccine-induced anti-CSP antibody immune responses. The study duration shall be 34 months and subject participation duration shall be 15-26 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasmodium Falciparum Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.8x10^6 sporozoites 2 doses

To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10\^6 sporozoites on study weeks 3 and 11. n=8

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

2.7x10^6 sporozoites 2 doses

To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10\^6 sporozoites on study weeks 5 and 13. n=8

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

2.7x10^6 sporozoites 3 doses

Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80

Group Type EXPERIMENTAL

Artesunate

Intervention Type DRUG

Four tablets of 50mg each, totaling 200mg will be given in a single calendar day

PfSPZ Vaccine

Intervention Type BIOLOGICAL

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Placebo

Intervention Type OTHER

Placebo

4.5x10^5 sporozoites 2 doses

Initial vaccination arm. Vaccination with 4.5x10\^5 sporozoites on study weeks 1 and 9. n=8

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

9x10^5 sporozoites 2 doses

Initial vaccination arm. Vaccination with 9x10\^5 sporozoites on study weeks 1 and 9. n=8

Group Type EXPERIMENTAL

PfSPZ Vaccine

Intervention Type BIOLOGICAL

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artesunate

Four tablets of 50mg each, totaling 200mg will be given in a single calendar day

Intervention Type DRUG

PfSPZ Vaccine

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention Type BIOLOGICAL

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A male or non-pregnant female aged 21-40 years inclusive at the time of screening.
2. For women, willingness not to become pregnant until 1 month after the last vaccination\*.

\*Pre-menopausal female participants will be referred to the local family planning clinic, which offers several means of contraception that are approved and recommended by the Burkina Faso Ministry of Health. Contraception (male or female condoms, diaphragm or cervical cap with spermicide, intrauterine device, or hormone-based contraceptive) should be started 30 days before the first vaccination and continue until 30 days after last vaccination.
3. Written informed consent obtained from the participant before screening.
4. Available and willing to participate in follow-up for the duration of study.
5. Residing in Sapone region and environs.
6. Appear to be in generally good health based on clinical and laboratory investigation.

Exclusion Criteria

1. Previous vaccination with an investigational malaria vaccine.
2. Use of an investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days before the first study vaccination, or planned use up to 30 days after last vaccination.
3. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months before the first vaccination\*.

\*This includes any dose level of oral steroids, but not inhaled steroids or topical steroids.
4. Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first study vaccination with the exception of tetanus toxoid.
5. Confirmed or suspected immunosuppressive or immunodeficient condition.
6. Confirmed or suspected autoimmune disease.
7. History of allergic reactions or anaphylaxis to artesunate and artemisinin derivatives, vaccinations or to any vaccine component.
8. History of serious allergic reactions to any substance, requiring hospitalization or emergent medical care.
9. History of allergy to any component of the vaccine formulation, including human serum albumin.
10. Use or planned use of any drug with anti-malarial activity during the course of the study except for antimalarial medication administered by study clinicians.
11. History of splenectomy.
12. Confirmed or suspected pregnancy or current breastfeeding.
13. Laboratory evidence of liver disease (ALT \> / = 1.25 x upper limit of normal).
14. Laboratory evidence of renal disease (serum or plasma creatinine \> upper limit of normal).
15. Laboratory evidence of hematologic disease (platelet count \<115,000/mm\^3, or hemoglobin \<11.2 g/dL for males and \<9.5 g/dL for females).
16. Seropositive for hepatitis B surface antigen or hepatitis C virus (hepatitis C antibody).
17. Seropositive for HIV.
18. Sickle cell trait carriage or sickle cell disease.
19. Administration of immunoglobulin and/or any blood products within the three months preceding the first study vaccination or planned administration during the study period. 20. Simultaneous participation in any other interventional clinical trial.

21\. Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, severe malnutrition, or any other clinical findings that may increase the risk of participating in the study\*.

\*As determined by the PI. 22. Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol. 23. Documented history of non-febrile seizures or atypical (complex) febrile seizures.

Minimum Eligible Age

21 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes